Coronary heart disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular events (MACE).
At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Foreign studies indicate that hsCRP ≥ 2mg / L is the definition standard of RIR in CAD. In China, there is no defined value of RIR for patients undergoing PCI, and the incidence of RIR has not been investigated clearly. At the same time, the impact of dynamic changes of hsCRP on MACE in PCI population needs to be further explored. Therefore, in this study, we plan to recruit patients undergoing PCI, and observe the impact of RIR by serial hsCRP measurements on the prognosis of these patients followed up for 5 years.
Participants who understand and sign the informed consent form voluntarily;
Age ≥ 18 years old and ≤ 80 years old, regardless of sex;
The hospitalized patients with coronary heart disease undergoing PCI;
Complete all planned PCI during hospitalization
Patients do not receive standardized treatment according to guidelines after being diagnosed with coronary heart disease;
Uncontrolled infectious diseases during the screening period;
In the screening stage, patients with immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumor and so on;
Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic drugs during the study period;
Patients with coronary heart disease completed all planned PCI during hospitalization
Cohort
Prospective
Not listed
Major adverse cardiovascular events (MACEs)
Composite endpoint of all-cause death, nonfatal myocardial infarction, nonfatal stroke, and revascularization due to ischemia
All-cause death
Death due to any cause
Cardiovascular death
Death due to cardiovascular cause
Nonfatal myocardial infarction
According to the fourth edition of the General Definition of Myocardial Infarction
Revascularization due to ischemia
Ischemia driven revascularization, including repeated PCI or CABG due to recurrent or persistent ischemic symptoms
Click on the lead sponsor to view all of their trials.
